Professor Dr. Mohammad H. Jamal

Professor Mohammad H. Jamal

One of the Middle East's leading hepatobiliary, bariatric and laparoscopic surgeons — combining surgical excellence, research and education to transform patient lives.

Professor of Surgery

American Board Certified Obesity Medicine Physician and Bariatric Surgeon

Researcher & Scientist

Speaker

Educator

Winner of Highest Scientific Award in Kuwait from KFAS

Performed The First Successful Liver Transplant Surgery in Kuwait

Introducing The Enhanced Recovery Protocol Bariatric Program in Kuwait

Book Appointment View CV Research Instagram

Portrait of Professor Dr. Mohammad H. Jamal

0Scientific Publications

0Years of Experience

0Successful Operations

0International Conference Presentations

Recognition

Selected achievements

Awards, leadership roles and academic milestones from an international surgical career.

View all achievements

2025

Professor of Surgery, Faculty of Medicine

Kuwait University

2023

Jaber Al-Ahmad Young Researcher Award

Kuwait Foundation for Advancement of Science

2020

Diplomate, American Board of Obesity Medicine

American Board of Obesity Medicine

2019

One of the first robotic bariatric surgery programs in the region

Research

Featured research

Peer-reviewed work advancing bariatric, metabolic and hepatobiliary surgery.

Explore the research

Short-term outcomes of endoscopic sleeve gastroplasty

Surgical Endoscopy • 2025

Endoscopic sleeve gastroplasty reshapes the stomach into a narrow tube using stitches placed through the mouth with an endoscope — no incisions, and no part of the stomach removed. It is offered to people who do not qualify for weight-loss surgery, or who would rather avoid it. This study followed 61 adults treated at a public hospital in Kuwait, the first such report from the country. Their average starting weight was 84 kg, with a BMI of 32.5. Weight came off steadily across the year: 10.6% of body weight by three months, 13.4% by six, and 16.1% by twelve months among the 49 people still being followed. More than half had lost over 15% of their weight at a year, and ten reached a BMI in the normal range. Side effects were mild — lasting nausea, constipation, and one stomach ulcer treated without surgery — and no patient needed an operation to correct a problem. Eleven patients were also taking semaglutide or tirzepatide and did not lose noticeably more than the rest. The authors note that the group was small, followed for only a year, and that cost and a shortage of trained specialists limit access in Kuwait.

Safety and effectiveness of two different fluid-filled intragastric balloons: a single center experience

Obesity Surgery (Springer) • 2024

Gastric balloons are a temporary, non-surgical option for people who want to lose weight but don't qualify for bariatric surgery, or don't want it. A soft balloon sits in the stomach so the person feels full sooner. This study from a private clinic in Kuwait compared two fluid-filled types in 358 adults. The Elipse is swallowed as a capsule, needs no endoscopy or sedation, and empties by itself after about four months. The Orbera365 is placed and removed by endoscopy under anaesthetic and stays in for a year. At the four-month mark the two performed almost identically, with around 10% of body weight lost. By the end of each treatment the Orbera365 group had lost more — 14.7% at twelve months, against 10.0% for the Elipse — but the researchers put this down to the longer time in place rather than the balloon itself. The trade-off was tolerance: 9.7% of Orbera365 patients needed the balloon taken out early, compared with 3.4% of Elipse patients, usually because they could not cope with it. Four patients across both groups developed pancreatitis. The study looked back at existing records, and weight regain after removal was not tracked.

Effect of dual glucagon-like peptide 1/glucose-dependent insulinotropic polypeptide receptor agonist (tirzepatide) versus bariatric surgery on weight loss and nonalcoholic fatty liver disease

Medical Principles and Practice (Karger) • 2024

Weight-loss injections are often compared with weight-loss surgery, but the two are rarely tested side by side. This laboratory study did exactly that — in rats, not people. Researchers in Kuwait fed rats a high-fat, high-sugar diet until they became obese, then divided them into groups: sleeve gastrectomy surgery, daily semaglutide, daily tirzepatide at one of three doses, and an untreated comparison group. Six weeks later, the surgery group had lost 15.5% of their body weight and the semaglutide group 10.7%. Tirzepatide's effect depended on the dose: the lowest dose produced only 5.0% weight loss, while the middle and highest doses produced 14.9% and 17.7%, matching or exceeding surgery. All the treatments improved how well the animals handled a sugar load, shrank their fat stores, and reduced the fat build-up in the liver that causes fatty liver disease. The highest tirzepatide dose gave the strongest results overall, including a drop in the deeper abdominal fat linked to insulin resistance. The authors stress that this was a short animal experiment, that the doses used cannot be translated directly to people, and that studies in humans are needed before any conclusions are drawn about patients.

News